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Abstract
Background: Detection of active tuberculosis (TB) before antiretroviral therapy (ART) initiation is important, but optimal
diagnostic methods for use in resource-limited settings are lacking. We assessed the prevalence of TB, evaluated the
diagnostic yield of Xpert MTB/RIF in comparison with smear microscopy and culture, and the impact of Xpert results on
clinical management in HIV-positive adults eligible for ART at health centers in a region of Ethiopia.
Methods: Participants were prospectively recruited and followed up at 5 health centers. Trained nurses collected data on
socio-demographic characteristics, medical history and symptoms, and performed physical examination. Two paired
morning sputum samples were obtained, and lymph node aspirates in case of lymphadenopathy. Diagnostic yield of Xpert
MTB/RIF in sputum was compared with smear microscopy and liquid culture.
Results: TB was diagnosed in 145/812 participants (17.9%), with bacteriological confirmation in 137 (16.9%). Among
bacteriologically confirmed cases, 31 were smear-positive (22.6%), 96 were Xpert-positive (70.1%), and 123 were culture-
positive (89.8%). Xpert MTB/RIF increased the TB detection rate by 64 cases (47.4%) compared with smear microscopy. The
overall sensitivity of Xpert MTB/RIF was 66.4%, and was not significantly lower when testing one compared with two
samples. While Xpert MTB/RIF was 46.7% sensitive among patients with CD4 cell counts .200 cells/mm3, this increased to
82.9% in those with CD4 cell counts #100 cells/mm3. Compared with Xpert-positive TB patients, Xpert-negative cases had
less advanced HIV and TB disease characteristics.
Conclusions: Previously undiagnosed TB is common among HIV-positive individuals managed in Ethiopian health centers.
Xpert MTB/RIF increased TB case detection, especially in patients with advanced immunosuppression. An algorithm based
on the use of a single morning sputum sample for individuals with negative sputum smear microscopy could be considered
for intensified case finding in patients eligible for ART. However, technical and cost-effectiveness issues relevant for low-
income countries warrant further study.
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Introduction
The recent achievements in mortality reduction in HIV-positive
individuals through the scale up of antiretroviral therapy (ART) in
sub-Saharan Africa have been dented by a high occurrence of TB,
which remains the leading cause of death [1,2]. Studies from
South Africa, Uganda and Tanzania have shown unrecognized
active TB in 7–31% of patients starting ART [3–5]. Atypical
disease manifestations and lack of suitable diagnostic tools
contribute to suboptimal TB case finding [5–7]. Delayed diagnosis
of TB increases the risk both of mortality and of immune
reconstitution inflammatory syndrome [4,8] in patients receiving
ART, and is also associated with TB transmission in health
facilities [9] and in the community [10]. In addition, isoniazid
preventive therapy (IPT) may be inadvertently administered to
patients with active TB [11].
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The World Health Organization (WHO) recommends regular
symptom screening for TB for HIV-positive individuals in TB-
endemic settings [12]. Although the overall sensitivity of the
current algorithm is 79%, its specificity is estimated at 50% [13],
indicating that a majority of patients identified will need further
investigations to ascertain their TB status. In most settings,
especially at primary health care level, the century-old acid fast
bacilli (AFB) smear microscopy is currently the only available
method to diagnose TB. In HIV-positive individuals the perfor-
mance of sputum smear microscopy is unsatisfactory; the
sensitivity of this technique in HIV-positive individuals starting
ART in South Africa was 22% and 26% using one and two
samples, respectively [14].
Mycobacterial culture is generally considered to have the
highest sensitivity for detection of Mycobacterium tuberculosis (Mtb),
and is generally used for reference in evaluation of alternative
techniques [15]; it is also the only method that can give
information on antibiotic sensitivity patterns. However, wide-
spread use of culture is compromised by protracted result delivery
[14], high upfront cost and strict requirement of advanced
biosafety precautions [6,16]. Furthermore, culture results may be
affected by antibiotic therapy, as well as storage and transport
conditions [17]. In resource-limited settings, mycobacterial culture
therefore mainly has a role for surveillance and for cases with
suspected drug resistance.
In December 2010, the WHO approved a new molecular assay-
based test, Xpert MTB/RIF, for the diagnosis of TB in HIV-
positive individuals [18]. This assay is an all inclusive molecular
test that uses real-time polymerase chain reaction (PCR) to amplify
a Mtb-specific sequence of the RNA polymerase gene (rpoB) [19].
This gene is probed with molecular beacons to detect rifampicin
resistance mutations which can be used as surrogate markers for
multidrug-resistant TB (MDR-TB) [19]. A 2013 Cochrane review
by Steingart et al summarized several evaluations of Xpert MTB/
RIF, demonstrating high overall sensitivity and specificity, albeit
mostly conducted in individuals with suspected pulmonary TB
[20]. Good diagnostic performance has also been shown for TB
lymphadenitis [21].
The lower detection limit of the assay has been estimated at
131 CFU/mL [19]; hence. the sensitivity of Xpert MTB/RIF is
directly related to the bacterial burden in the specimen, and
consequently correlates with sputum smear status [22]. The higher
occurrence of paucibacillary forms of pulmonary TB in HIV-
positive individuals could explain the lower sensitivity found in
such patients [22,23]. Yet, the lack of accurate diagnostic methods
and the poor prognosis of TB in HIV-infected subjects suggest that
these are the ones who may benefit most from the introduction of
Xpert MTB/RIF. This test has been evaluated for TB screening
before starting ART in a cohort from South Africa; Xpert MTB/
RIF increased detection rates of TB by 45% compared with smear
microscopy [14]. Although sensitivity was reduced for smear-
negative TB, patients detected by Xpert MTB/RIF were
characterized by more advanced immunosuppression as compared
to Xpert-negative cases [24].
Despite promising preliminary results and the WHO endorse-
ment, the actual role of Xpert MTB/RIF in resource-constrained
settings endemic for HIV and TB is unclear, especially considering
drawbacks of this method such as cost, requirement of ambient
temperature below 28uC, uninterrupted power supply and
consumables [25]. In particular, the use of this test for TB
diagnosis in HIV-positive individuals managed at health centers –
where around 60% of TB patients globally are treated [26] - has
not been evaluated.
In 2011 Ethiopia had the 7th highest level of incident TB among
the 22 high burden countries worldwide [27]. The reported rate of
HIV infection among TB patients was 18% in 2008 [28]. Data on
the prevalence of bacteriologically confirmed TB among HIV-
positive individuals in Ethiopia is limited to a hospital-based study
conducted in the capital Addis Ababa in 2006, in which 32 of 438
study participants (7%) were found to have positive sputum
cultures for TB [29].
Access to ART has increased rapidly in Ethiopia since 2006,
when decentralization of HIV care to health centers was
introduced [30]. The proportion of patients receiving ART
through health centers has increased in Ethiopia, and is expected
to rise further [31].
In this study, we have determined the prevalence of TB among
HIV-positive adults eligible to start ART at public health centers
in an uptake area in central Ethiopia. We have also evaluated the
diagnostic yield of Xpert MTB/RIF compared with sputum smear
microscopy, using liquid culture for reference, as well as the
impact of Xpert MTB/RIF testing on patient management.
Materials and Methods
Settings
This study was conducted in all public health centers (Mojo,
Adama, Geda, Dhera and Wolenchiti) providing ART services for
residents in Adama town and adjacent rural and suburban districts
of Oromia Region of Ethiopia (total population of the uptake area
around 600,000). These 5 health centers are located on the
highway connecting Addis Ababa and Djibouti, which is
considered to be a high risk corridor for HIV infection in
Ethiopia. In 2005, Adama, the major town on the highway, had a
HIV prevalence of 9% as compared to the national prevalence of
3.5% [32].
In health centers, nurses or health officers (with 4 years of
academic training) are entirely in charge of patient care, including
ART initiation and follow up. The National Program Guidelines
in practice at the time of this study recommended ART initiation
in all patients with CD4 cell counts of 200 cells/mm3 or lower; as
well as for individuals in WHO clinical stage 3 with CD4 cell
counts of 350 cells/mm3 or lower, and in patients in WHO clinical
stage 4 regardless of CD4 cell level [33].
Study Participants
Individuals aged 18 years or greater were eligible for inclusion if
they were diagnosed with HIV (based on rapid tests), had a
previously documented CD4 cell count lower than 350 cells/mm3
on at least one occasion, or had WHO stage 4 disease, and resided
in the catchment area of any one of the 5 health centers. For
inclusion participants were also required to submit at least one
morning sputum sample. Patients who were taking ART, or
reported previous use of ART, as well as patients who had
received TB treatment for more than 2 weeks prior to inclusion
were excluded. The presence of symptoms suggestive of TB was
neither used as a criterion for inclusion nor exclusion.
Methods
Consecutive HIV-positive individuals presenting to the study
health centers during the inclusion period (October 3, 2011 to
March 1, 2013) were screened for eligibility. All study procedures,
were performed by health center staff who had received detailed
and repeated training on the study protocol.
Following inclusion, the study staff at the respective health
center collected information using a standardized paper question-
naire on socio-demographic characteristics, medical history and a
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range of symptoms potentially associated with TB. Current or
previous receipt of IPT and cotrimoxazole prophylaxis was also
registered. In addition, structured physical examination was
performed. Participants were provided with four separate tubes
and asked to submit two paired simultaneously and spontaneously
expectorated morning sputa to the health center laboratory on
consecutive days. Fine needle aspirates (FNA) were obtained from
patients found to have peripheral lymphadenopathy of .1 cm
(.2 cm for inguinal lymph nodes) size. In addition, blood samples
were obtained for CD4 cell testing and hematological parameters.
TB bacteriological test results were communicated to the
respective health center staff, who contacted patients for initiation
of TB therapy. The study participants could also be initiated on
anti-TB treatment by their health provider in case of strong
clinical suspicion and positive radiologic findings in accordance
with National TB Program Guidelines [34]. With the exception of
the intensified TB case finding and regular monitoring by the
research team, all other components of patient care were at the
discretion of the attending clinicians. At two months after TB
diagnosis, study participants were assessed for initiation of
treatment, retention in care and mortality.
Data quality was ensured through weekly monitoring at each
site by the investigators (TTB and PB). Data was entered into excel
files in real time and cross-checked with hard copies by trained
project data clerks.
TB Diagnosis
Trained laboratory technicians at each health center instructed
study participants on how to deliver adequate sputum samples. A
volume of 1.5 ml of morning sputum that was free of solid particles
was considered to be adequate in volume and quality. In case of
inadequate samples, participants were asked to repeat submission.
On both mornings, one arbitrarily selected sputum sample was
delivered to the Adama Regional Laboratory, where Xpert MTB/
RIF assay (Cepheid, Sunnyvale, CA) and smear microscopy were
performed. The second sputum sample was sent to International
Clinical Laboratories (ICL), a private laboratory located in Addis
Ababa, for detection of Mtb using liquid culture. Lymph node
samples were obtained using fine needle aspiration by a
pathologist at a private laboratory in Adama, and were subjected
to culture and Xpert MTB/RIF. Health center laboratory
personnel transported sputum samples by car to Adama Regional
Laboratory and ICL sample collection site in Adama twice a week
with strict adherence to cold chain system (distance of 30 minutes).
Participants were instructed to submit sputum samples on these
week days in order to avoid storage before testing. From the
collection site, samples were transferred to ICL in Addis Ababa on
a daily basis (travelling distance of about one and half hours by
car).
Adama Regional Laboratory is a regional reference laboratory,
and is responsible for external quality assurance for hospitals and
health centers in Oromia region. ICL is accredited by the Joint
Commission.
Before initiation of the study, hands-on training regarding the
operation of the assay was provided to the laboratory technologists
performing the Xpert MTB/RIF assay. N-acetyl-L-cysteine and
sodium hydroxide (NALC-NaOH) decontaminated sputum and/
or lymph node aspirate samples were tested by four-module device
Xpert MTB/RIF assay following the manufacturer’s instructions.
After the manufacturer’s reagent was mixed with 1 ml sputum at
2:1 ratio, 2 ml of the homogenized mixture was transferred into
the disposable cartridge and inserted into the GeneXpert
instrument. As soon as the test results were ready, they were
delivered to the attending clinicians to inform on subsequent
patient management. The Xpert MTB/RIF results may be
inconclusive due to failure of the internal PCR control (termed
‘‘invalid’’ result), or due to premature interruption of the reaction
(termed ‘‘error’’ result); for this study both of these test outcomes
were considered as failed tests. Study participants with two failed
Xpert results were managed based on the liquid culture results.
Uninterrupted power supply was maintained during test perfor-
mance. Both the instrument and the cartridges were kept at
ambient temperature not exceeding 28uC. The instrument was
calibrated according to the manufacturer’s instructions after it had
been in use for a year.
Direct smear microscopy for AFB was performed using Ziehl-
Neelsen staining on the same sputum sample that was used for
Xpert MTB/RIF. The test results were reported in accordance
with WHO/International Union Against Tuberculosis and Lung
Diseases recommendations [35]. Smear microscopy was per-
formed by two laboratory technologists (with more than 5 years’
experience) throughout the study period. As an internal quality
control, blinded cross-checking of slides included in this study was
practiced on a weekly basis by the laboratory technologists. When
new batches of reagents were prepared for smear microscopy,
positive and negative controls were tested before study samples to
ensure the quality of the reagent. Daily maintenance of the
microscope was conducted.
For external quality control 5 AFB stained and 5 non-stained
slides received from the national reference laboratory, EHNRI
(Ethiopian Health and Nutrition Research Institute, Addis Abeba)
were assessed two times per year. The test panel showed adequate
staining procedures and evaluation of prestained slides and the
error rate was zero throughout the study period.
BACTEC MGIT (Mycobacterial Growth Indicator Tubes) 960
system (BD Diagnostics, Franklin Lakes, NJ) was used for primary
culture of Mtb. The identity of any growth was confirmed by the
Capilia TB speciation assay (TAUNS, Numazu, Japan). MGITs
were inoculated and incubated for up to 42 days and the culture
time-to-positivity (TTP) was recorded. Negative culture results
were reported if no growth was detected in MGIT or if growth of a
mycobacterium other than MTB was observed. The internal
quality control for mycobacterial culture included two negative
controls consisting of distilled water in addition to each batch of
patient samples. One of the negative controls was used as a quality
check for the reagent, and the other negative control was used to
monitor the prescence of cross contamination. In addition, the M.
tuberculosis H37Rv (ATCC 27294) strain was processed as a
positive control together with the patient samples once a week.
Positive cultures were checked against adjacent culture results to
detect any risk of cross contamination. All culture results were
logged consecutively.
The laboratory staff at both laboratories was blinded to patient
clinical characteristics and the TB test results from the other
laboratory.
Complete blood count was done using a Sysmex KX-21
(Sysmex Corporation, Kobe, Japan). Likewise, measurements of
CD4 cells counting tests were performed with the use of flow
cytometry (FACS Calibur, Becton Dickinson).
Ethical considerations
Ethical approval was obtained from the National Research
Ethics Review Committee at the Ministry of Science and
Technology of Ethiopia and the Regional Ethical Review Board,
Lund University, Lund, Sweden. All study participants provided
written informed consent. An impartial witness confirmed consent
received from illiterate study participants.
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Statistical analysis
Participants with at least one positive result by smear
microscopy, Xpert MTB/RIF or culture were considered as
bacteriologically confirmed TB cases [36]. Participants with
clinically suspected TB (according to National TB Program
Guidelines), and who initiated TB treatment, were categorized
as clinically diagnosed cases. Participants in whom TB was not
detected using smear microscopy, Xpert MTB/RIF or liquid
culture, and in whom TB was not clinically suspected nor treated
empirically were defined as non-TB cases.
For evaluation of the diagnostic performance of Xpert MTB/
RIF, comparison was made for smear microscopy, using culture
results for reference. This analysis included only participants with
at least one sample that had been tested with all three methods.
Only results from sputum samples were used for this comparison.
Hence, patients with positive TB test results obtained exclusively
from lymph node aspirates were excluded, as well as those with
clinically diagnosed TB. Since culture was used as a reference for
this analysis, patients with contaminated cultures were also
excluded; however, we included patients with failed Xpert
MTB/RIF results in order to get an accurate estimate of the
real-life performance of this method in the study setting.
Statistical analysis was performed using IBM SPSS 20.0 for
Windows. Pearson’s Chi-Square test was used in univariate
analysis in two-by-two tables for dichotomized variables. Com-
parisons of medians using non-parametric Mann-Whitney’s U-test
were performed for scale variables that were not visually normally
distributed (confirmed by skewness calculation)
Smear microscopy and Xpert MTB/RIF results were compared
using liquid culture for reference. Sensitivity, specificity, positive
predictive value (PPV), and negative predictive value (NPV) were
calculated with 95% confidence intervals (95% CIs). All statistical
tests were two-sided with a p-value,0.05 considered significant.
Results
Patient characteristics
A total of 886 eligible HIV-positive individuals were initially
included. However, for 13 of these (with WHO clinical stage lower
than 4) no previous CD4 cell count result below 350 cells/mm3
could be identified; hence, these subjects were excluded. Further-
more, an additional 61 participants were excluded since they did
not deliver sputum samples.
Thus, a total of 812 (336 male, 476 female) study participants
with a median age of 32 years (IQR, 28–40) submitted at least one
pair of simultaneously expectorated morning sputum samples and
were included in the analysis (Figure 1).
The characteristics of the study participants are presented in
Table 1. Among them 559 had been enrolled in HIV care before
the study was initiated, whereas 253 were newly registered patients
at the respective health center. The median CD4 cell count at
baseline was 209 cells/mm3 (IQR, 118–321). Fifty-one (6.3%)
reported a prior episode of TB. Although more common among
TB patients (93% vs. 78%; p,0.001), 80% of study participants
had a positive WHO symptoms screen (presence of either cough,
fever, night-sweating or weight loss).
A total of 1,514 sputum samples were obtained from the study
participants. While two paired morning sputum samples were
obtained from 702 study participants, 110 participants submitted
only one pair of morning sputum samples. Lymph node aspirates
were obtained from 22 study participants.
Tuberculosis Prevalence
TB was diagnosed in 145/812 participants (17.9%); in 137
(16.9%) bacteriological confirmation was obtained. Thirteen
(9.5%) of the confirmed TB cases were on TB treatment (for a
maximum of 2 weeks) at inclusion. Further, 8 study participants
had clinically diagnosed TB (without bacteriological confirmation).
TB was not diagnosed in the remaining 667 study participants.
Bacteriological TB Diagnosis
A total of 1,536 sputum and FNA samples were tested using
smear microscopy, Xpert MTB/RIF and liquid culture. Ninety-
five (6.2%) of the samples analysed using Xpert MTB/RIF were
failed tests (81 error and 14 invalid results), whereas 19 (1.2%)
culture samples were contaminated.
Of the 137 bacteriologically confirmed TB patients, 123 (89.8%)
were culture positive and 13 (10.2%) were culture-negative. A total
of 96 participants were Xpert-positive for TB; among these, 2 were
only Xpert-positive in lymph node aspirates, whereas the
remaining 94 cases were detected in sputum samples. Rifampicin
resistance mutations were detected by Xpert MTB/RIF in 2 cases.
Thirty-one patients were sputum smear-positive (Table 2).
Culture results were not available for one Xpert-positive TB
patient due to contamination of both morning sputum samples.
For one patient both Xpert tests failed; both TB cultures for this
subject were negative. Of the 13 Xpert-positive culture-negative
TB cases, 3 had received TB treatment for less than 2 weeks when
sputum samples were obtained.
The median culture TTP for Xpert-positive and Xpert-negative
cases were 10 days (IQR, 7–13) and 13 days (IQR, 8–15),
respectively (p=0.041). Based on indications given by the Xpert
assay, the following proportions of Xpert-positive patients were
observed with regard to assay load: 37 (38.5%) had very low Xpert
assay load, 37 (38.5%) had low Xpert assay load, 19 (19.8%) had
medium Xpert assay load and 3 (3.1%) had high Xpert assay load.
Higher Xpert assay load was associated with AFB smear positivity
(p,0.001) and shorter median culture TTP (p,0.001).
Diagnostic yield of Xpert MTB/RIF in Sputum Compared
to Smear Microscopy and Culture
Using smear microscopy for comparison, Xpert MTB/RIF
increased the TB case detection rate by 64 (47.4%) cases.
Furthermore, the Xpert MTB/RIF detected 14 (10.2%) TB cases
with negative (13 patients) or contaminated culture result (1
patient). Compared to 31 cases detected by sputum smear
microscopy (22.6%), 94 cases of pulmonary TB were detected
by culture, increasing the case detection rate by 70.1%.
Among 94 participants with Xpert-positive sputum samples 30
(32%) were smear-positive and 64 (68%) were smear-negative. For
the 122 culture-positive cases, 28 (23%) and 94 (77%) were smear-
positive and negative, respectively. Of 104 smear-negative TB
cases, 54 (52%) were positive using both Xpert and culture and 40
(38%) were positive only using culture. All smear-positive TB
patients were either Xpert- or culture-positive (Table 2).
Overall, 81 [66.4% (95% CI, 57.2–74.6)] of the culture-positive
TB cases were Xpert-positive. The sensitivity using the first
morning sputum sample was 57.4% as compared to 67.6% for two
samples. In this cohort, the difference in sensitivity between using
one or two morning sputum samples was not significant
(p=0.729). The sensitivity of Xpert MTB/RIF assay was 96.4%
(95% CI, 79.7–99.9) and 57.4% (95% CI, 46.8–67.5) among
sputum smear positive and negative TB cases, respectively.
Whereas the sensitivity of the Xpert MTB/RIF was 46.7%
(95% CI, 31.9–62.0) for participants with CD4 cell counts .200
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cells/mm3, it increased to 82.9% (95% CI, 65.7–92.9) in patients
with CD4 cell counts #100 cells/mm3. A similar increase in
sensitivity was observed with increasing WHO clinical stages
(Table 3).
Using culture for reference, the Xpert MTB/RIF had a
specificity of 98.4% (95% CI, 97.0–99.2), and a PPV and a
NPV of 88.0% (95% CI, 79.2–93.6) and 94.2% (95% CI, 92.1–
95.8), respectively (Table 3).
The sensitivity of smear microscopy was 23% (95% CI, 16.0–
31.7) (Table 3). The sensitivity was slightly lower (19.7%;95% CI,
13.2–28.1) when only the first morning sputum sample was used
for analysis.
Characteristics of TB patients with regard to sputum
Xpert results and smear status
In this cohort, smear-positive and smear-negative Xpert-positive
TB patients had similar clinical characteristics; as shown in table 4,
these two groups of patient did not differ significantly with regard
to age, gender, BMI, absolute CD4 cell count and WHO clinical
stage. In contrast, Xpert-positive and Xpert-negative TB patients
displayed significant differences. Xpert-positive TB patients had
significantly lower BMI (p=0.043) and absolute CD4 cell count
(p=0.006), and higher WHO clinical stage distribution prior to
TB screening (p=0.001) (Table 5).
Patient Management Implications of Xpert MTB/RIF TB
Diagnosis
The turnaround time for Xpert MTB/RIF was about 2 hours.
In the Xpert-positive TB patients, the median time-to-TB
treatment (time from inclusion in the study to initiation of TB
treatment) was 9 days (IQR, 6–21) and only 8 (10%) of these
initiated ART before starting TB treatment.
The median time-to-TB treatment was 46 days (IQR, 34–60)
for Xpert-negative culture-positive TB patients. Consequently, a
substantial proportion of Xpert-negative TB cases (49%) started
ART before TB treatment (P,0.001) (Table 6).
The median culture TTP for smear-negative TB cases was 12
days (IQR, 8–14) and the median time-to-TB treatment was 20
days (IQR, 6–42). The median culture TTP was 8 days (IQR, 7–
10) and the median time-to-treatment was 8 days (IQR, 3–18) for
smear-positive TB cases. While 73 (90%) of culture-positive Xpert-
positive TB patients started TB treatment within 2 months after
inclusion, only 23 (55%) of culture-positive Xpert-negative TB
patients started treatment during the same time interval (p,0.001)
(Table 6).
Comparing Xpert-positive and Xpert-negative culture-positive
TB patients, the significant difference in time-to-TB treatment did
not translate into a significant difference in 2 month mortality
(p = 0.70) (Table 6).
Figure 1. Flow chart of the study participants.
doi:10.1371/journal.pone.0085478.g001
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Discussion
The intensified case finding approach applied in this investiga-
tion revealed a high prevalence (16.9%) of bacteriologically
confirmed TB in HIV-positive adults residing in an uptake area
in central Ethiopia. In only a minority of these cases had TB co-
infection been considered prior to study inclusion. Importantly,
these subjects were recruited in public health centers, which are
the health facilities where increasing proportions of HIV-positive
individuals in sub-Saharan Africa are managed. The rate of TB
detected in our study is much greater than that found in the only
previously published investigation on TB in HIV-positive adults
performed in Ethiopia [29], and is in the range of prevalence
figures reported from South Africa [14,16,37], considered to be
among the highest for TB in HIV-positive individuals globally
[38]. Although restricted to one geographical area, our findings
suggest a considerable burden of unrecognized TB among HIV-
positive individuals in Ethiopia, and highlight the need of
improved diagnostic strategies that can also be used in facilities
with limited resources.
Table 1. Characteristics of the study participants by TB diagnosis.
Characteristics** Variables Total No (%) TB diagnosed* No (%)
TB not diagnosed No
(%) p-value
Total Cohort (%) 812(100) 145 (17.9) 667 (82.1)
Patient Characteristics
Gender Male 336 (41) 76 (52) 260 (39) 0.003
Female 476 (59) 69 (48) 407 (61)
Age (years) Median age (IQR) 812 (100) 35 (28–42) 32 (28–38) 0.027
Residence Urban 633 (79) 110 (78) 523 (79) 0.678
Rural 168 (21) 31 (22) 137 (21)
BMI (kg/m2) Median BMI (IQR) 805 (99) 18 (16–20) 19 (18–21) ,0.001
WHO symptom screening*** Positive 646 (80) 134 (93) 512 (78) ,0.001
Negative 159 (20) 10 (7) 149 (22)
WHO clinical stage (prior to TB
screening)
I 141 (17) 12 (8) 129 (19) ,0.001
II 246 (31) 28 (19) 218 (33)
III 322 (40) 71 (49) 251 (38)
IV 100 (12) 34 (24) 66 (10)
CD4 cell count (cells/mm3) Median absolute CD4 cell count
(IQR)
806 (99) 172 (93–274) 220 (123–328) ,0.001
CD4 percentage 798 (99) 12 (8–16) 13 (8–17) 0.362
CD4 cell strata(cells/mm3)
.200 426 (53) 57 (39) 369 (55.8) ,0.001
101–200 223 (28) 47 (33) 176 (26.6)
#100 157 (19) 41 (28) 116 (17.5)
Hemoglobin (g/dl) 761 (94) 10 (9–12) 12 (10–13) ,0.001
HIV care
Enrolment History
Newly enrolled 253 (31) 59 (41) 194 (29) 0.006
In HIV care 559 (69) 86 (59) 473 (71)
On IPT{
Yes 19 (2) 1 (1) 18 (3) 0.145
No 790 (98) 144 (99) 646 (97)
On CPT`
Yes 612 (76) 107 (74) 505 (76) 0.552
No 196 (24) 37 (26) 159 (24)
Previous History of TB Yes 51 (6) 5 (3) 46 (7) 0.176
No 749 (94) 139 (97) 610 (93)
*Including both bacteriologically confirmed and clinical cases of TB.
**Number of missing observations: residence = 11, BMI = 7, WHO Symptom Screening = 7, WHO Clinical Stage = 3, median CD4 cell count = 6, CD4 percentage = 14, CD4
cell strata = 6, Hemoglobin = 51, IPT = 3, CPT = 4, previous TB history = 12.
***A positive WHO symptom screen is defined as the presence of either cough, fever, night-sweating or weight loss.
{IPT = INH preventive therapy.
`CPT = cotrimoxazole preventive treatment.
doi:10.1371/journal.pone.0085478.t001
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Most evaluations of Xpert MTB/RIF have targeted patients
with clinically suspected TB [20]. Yet, Xpert MTB/RIF is being
considered for screening HIV-infected subjects for active TB in
highly endemic settings [39], both due to greater TB prevalence
among such persons, as well as due to increased TB disease
severity. To our knowledge, the performance of Xpert MTB/RIF
for TB screening in patients eligible to start ART has only been
addressed previously in one published study from South Africa
[14]. Overall, our findings were similar to those reported by Lawn
et al [14], with an additional diagnostic yield using Xpert MTB/
RIF in sputum of 47.4%, and an overall diagnostic performance of
66.4% (using liquid culture for reference). In agreement with other
reports [14,23], we also found correlations between Xpert MTB/
RIF results and median culture TTP, as well as sputum smear
status; reflecting a higher threshold of colony-forming units in the
specimen for Xpert MTB/RIF detection as compared to liquid
culture.
Interestingly, although paucibacillary manifestations of pulmo-
nary TB are common in HIV-positive individuals [6,40], patients
with Xpert-negative culture-positive TB in our cohort had less
advanced immunosuppression than those with a positive Xpert
result. Smear-negative Xpert-positive patients had similar charac-
teristics to those with smear-positive disease, and smear-positive
TB was somewhat unexpectedly associated with more advanced
immunosuppression. The overall sensitivity of Xpert MTB/RIF
was also highest in the subset of patients with the most advanced
immunosuppression (82.9% in patients with CD4 cell count #100
cells/mm3 as compared to 46.7% in patients with CD4 cell counts
.200 cells/mm3). Although these findings are similar to those
reported by Lawn et al [24], they are in contrast to other
investigations on the association between bacterial burden and
CD4 cell counts in HIV-infected subjects performed in TB clinics;
in a South African study, the sensitivity for Xpert in subjects with
CD4 cell counts below 200 cells/mm3 was lower compared to
those with higher levels [23]. Similarly, higher bacillary density
among smear-positive HIV-infected patients in Tanzania corre-
lated with increasing CD4 cell levels [41]. One reason for this
discrepancy could be that our screening approach led to detection
of early-stage disease in subjects who had not yet developed
symptomatic TB [5]. Asymptomatic (or subclinical) TB has been
detected in considerable proportions of persons living in settings
with high TB incidence, especially in HIV-positive individuals
[37,42].
Given the superior detection rate of Xpert MTB/RIF
compared to smear microscopy, it has been suggested to introduce
this method as a replacement for the latter technique [14]. Such a
strategy has been estimated to be cost-effective in the South
African context [23], but it is unclear whether this also applies for
other countries on the continent [25].
Although the performance of sputum smear microscopy was
clearly inferior to that of Xpert MTB/RIF in our cohort, this
cheap, robust and well established method still detected 22.6% of
TB patients. Furthermore, no false positive smear results were
observed. In our opinion, Xpert MTB/RIF should rather be
considered as an adjunct test for improved case detection in smear-
negative HIV-positive individuals in low-income settings, instead
of replacing smear microscopy. Our data indicate that testing a
single morning sputum sample is sufficient for this purpose. In
contrast to other studies on Xpert MTB/RIF performance [14],
we did not find a significantly increased detection rate by using
two instead of one sputum sample for Xpert MTB/RIF testing.
This might be explained by the use of morning sputa (which have
higher bacterial load in TB patients) instead of samples obtained in
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Furthermore, clinical characterization of subsets of HIV-
positive individuals who would benefit most from Xpert MTB/
RIF testing could help to optimize testing algorithms in regions
with restricted resources. However, the WHO clinical screening
algorithm showed unsatisfactory specificity in this regard, since
78% of participants in our cohort without TB had a positive
WHO symptom screen, illustrating the need for algorithms with
greater specificity.
Our findings indicate that HIV/TB co-infected patients
detected by Xpert MTB/RIF have more severe disease, both
with regard to TB and HIV. Similar to a report from South Africa
[24], cases missed by Xpert MTB/RIF did not show higher two-
month mortality, despite significantly delayed initiation of TB
treatment. The true impact on patient survival of Xpert screening
is still difficult to estimate, since the outcome of persons with false
negative Xpert results in a context without access to culture (and
who would not receive TB treatment) might have been worse than
observed here. Even if Xpert MTB/RIF testing provided rapid
results, all Xpert-positive patients did not start TB treatment,
mostly because of early loss to follow-up.
Twelve patients had positive Xpert MTB/RIF results but no
bacterial growth in liquid culture. In line with revised WHO case
definitions [36] we used sputum smear, culture or Xpert MTB/
RIF as case definitions for TB. The significance of Xpert-positive
Table 4. Characteristics of smear-negative Xpert-positive patients compared to smear-positive cases.







Gender Male (%) 54 (57) 16 (53) 38 (59) 0.581
Female (%) 40 (43) 14 (47) 26 (41)
Age Median age (IQR) 35 (25–40) 35 (29–40) 36 (28–43) 0.638
BMI Median BMI (IQR) 17.5 (16–19) 17 (15–19) 18 (16–19) 0.259
CD4 cell count Median CD4 cell count (IQR) 94 (100) 128 (63–186) 170 (82–240) 0.179
CD4 cell strata .200 cells/mm3 (%) 28 (30) 6 (20) 22 (35) 0.317
101–200 cells/mm3 (%) 33 (35) 11 (37) 22 (34)
#100 cells/mm3(%) 33 (35) 13 (43) 20 (31)
WHO clinical stage (prior
to TB screening)
I 4 (4) 1 (3) 3 (5) 0.312
II 13 (14) 7(23) 6 (9)
III 53 (56) 16 (54) 37 (58)
IV 24 (26) 6 (20) 18 (28)
Previous history of TB Yes (%) 4 (4) 1 (3) 3 (5) 1.0
No (%) 89 (96) 29 (97) 60 (95)
doi:10.1371/journal.pone.0085478.t004
Table 5. Characteristics of Xpert-positive and Xpert-negative TB cases (all smear-negative and culture-positive).





Gender Male (%) 46 (49) 31 (57) 15 (39) 0.071
Female (%) 47 (51) 23 (43) 24 (61)
Age Median age (IQR) 35 (28–43) 36 (28–44) 32 (28–40) 0.261
BMI Median BMI (IQR) 18 (16.5–20.5) 18 (16–19) 20 (16–22) 0.043
CD4 cell count Median CD4 cell count (IQR) 94 (100) 167 (85–212) 211 (145–330) 0.006
CD4 cell strata .200 cells/mm3 (%) 38 (41) 16 (30) 22 (56) 0.029
101–200 cells/mm3 (%) 32 (34) 21 (39) 11 (28)
#100 cells/mm3 (%) 23 (25) 17 (31) 6 (16)
WHO clinical stage (prior
to TB screening)
I 11 (12) 3 (6) 8 (21) 0.001
II 20 (22) 6 (11) 14 (36)
III 43 (46) 30 (56) 13 (33)
IV 19 (20) 15 (28) 4 (10)
Previous history of TB Yes (%) 2 (2) 2 (4) 0 (0) 0.220
No (%) 90 (98) 51 (96) 39 (100)
doi:10.1371/journal.pone.0085478.t005
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culture-negative results has been discussed [23]; in accordance
with other researchers, we do not consider such cases as false
positive reactions [23,44] One reason for this phenomenon could
be that we used paired sputum samples for culture and Xpert
MTB/RIF, and it is possible that the bacterial content in those
samples (although obtained simultaneously) might have differed.
This fact should also be taken into account when interpreting data
on the performance of Xpert MTB/RIF performance using
culture for reference.
Despite being executed by trained laboratory technologists, the
occurrence of test failure was high (6.2% of samples tested). Apart
from this observation, the requirement of stable electric power,
temperature below 28uC and constant supply of consumables all
represent major obstacles for the roll-out of Xpert MTB/RIF
assay in the health systems of low-income countries.
This study was based on a large and well characterized cohort of
HIV-infected adults, and provides new and much needed data on
the TB prevalence among such individuals in Ethiopia. Our study
participants were recruited from several public health centers
providing ART in a defined uptake area, and we consider this to
give more accurate estimates, both of the true TB prevalence in
this context, as well as of the real-world performance of Xpert
MTB/RIF. Determination of TB prevalence was based on several
bacteriological diagnostic methods, using two paired morning
sputum samples, as well as lymph node aspirates from patients
with lymphadenopathy, which probably led to increased TB case
detection in the study population.
In our study population, the majority of participants (both with
and without final TB diagnosis) reported a positive WHO TB
symptom screen. This illustrates the considerable overlap of
disease symptoms in TB and HIV/AIDS. Although we did not
specifically target subjects with suspected TB symptoms for this
study, it is possible that the requirement of sputum samples for
inclusion might have led to some bias with regard to the presence
of airway symptoms. Since we did not collect other respiratory
samples for mycobacterial diagnostic testing (eg. gastric aspirate or
broncheo-alveolar lavage), we were unable to determine the rate of
TB in the minor proportion of potential study participants who did
not submit sputum samples (61/886; 6.9%), and whether this
would have affected the overall prevalence figure. Furthermore,
our study protocol did not include any diagnostic method for
extrapulmonary manifestations of TB apart from peripheral
lymphadenitis. This could have led to some underestimate of the
prevalence of active TB in the population. The fact that we
included patients who had initiated TB therapy during the
preceding two weeks might have influenced culture positivity rates;
still, the number of such cases was small, and only 3 of these 13
cases were culture-negative. This study did not aim to assess the
prevalence and characteristics of drug resistance in detected TB
strains, and phenotypic drug resistance patterns were not
available. Data on MDR TB from Ethiopia are limited; reports
suggest that the prevalence among patients without previous TB is
low [27], and few of our participants reported prior TB treatment.
Xpert MTB/RIF detected rifampicin resistance mutations in two
cases (who were referred for further evaluation in tertiary centers
in Addis Ababa). In settings with low prevalence of MDR TB it
has been recommended to interpret positive Xpert results for
rifampicin resistance with caution, since false positive reactions
may occur [14,45].
In conclusion, we found a high prevalence of previously
undiagnosed TB in HIV-infected adults seeking care in health
centers in central Ethiopia, illustrating the need of optimized
screening strategies for TB in this population. Using Xpert MTB/
RIF as part of such a screening algorithm in combination with
smear microscopy would lead to increased case detection,
especially in subjects with advanced immunosuppression. Yet, a
significant subset of HIV-positive patients with active TB would
still be missed using this technique, and the long-term outcomes of
such individuals warrant further study. Furthermore, technical and
cost-effectiveness issues have to be solved before general introduc-
tion of this diagnostic method can be considered.
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Table 6. Short-term implications of Xpert MTB/RIF on patient management; Xpert-positive compared to Xpert-negative TB cases.







Median time-to-TB treatment (IQR)* Days 15 (6–39) 9 (6–21) 46 (34–60) ,0.001
ART initiated before TB treatment no(%) Yes 24 (22) 8 (10) 16 (49) ,0.001
No 86 (78) 69 (90) 17 (51)
Started TB treatment within 2 months of
inclusion no(%)
Yes 96 (78) 73 (90) 23 (55) ,0.001
No 27 (22) 8 (10) 19 (45)
Died within the first 2 months no(%) Yes 8 (8) 5 (7) 3 (9) 0.699
No 96 (92) 67 (93) 29 (91)
*Time-to-TB treatment is defined as the time interval between date of inclusion and TB treatment start date (11 patients who never initiated TB treatment excluded).
Patients with clinically diagnosed TB (without bacteriological confirmation) and patients with positive results on lymph node aspirates (but without positive results in
sputum) excluded.
doi:10.1371/journal.pone.0085478.t006
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